New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance TEL AVIV, Israel, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage...

Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219 Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries TEL AVIV, Israel, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”)...

ALERT: Rosen Law Firm Reminds Kitov Pharmaceutical Holdings Ltd. Investors of Important Deadline in Class Action - KTOV NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Kitov Pharmaceutical Holdings Ltd. securities (NASDAQ:KTOV) pursuant and/or...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Kitov Pharmaceutical Holdings Ltd. - KTOV NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Kitov Pharmaceutical Holdings...